The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily is
superior to placebo in the treatment of participants with moderately to severely active
Rheumatoid Arthritis (RA) who have had an inadequate response to a tumor necrosis factor
(TNF) inhibitor, despite ongoing treatment with conventional disease-modifying antirheumatic
drugs (cDMARDs).